Barbican Dental Care has been acquired by Bupa Dental Services
The shareholders of Barbican Dental Care have sold the company to Bupa Dental Services (Bupa), the UK-based international healthcare group. Financial terms of this transaction have not been disclosed.
Barbican Dental Care is a specialist corporate dental business, offering affordable private dental care and corporate dental plans to companies based in the City, West End and Canary Wharf. The 24 surgeries operate from nine sites providing general, specialist and cosmetic dentistry.
Bupa provides international healthcare support and advisory services. This transaction meets Bupa’s strategy to acquire high quality private practices based in locations that are convenient for corporate and business centers.
Neil Sikka, who founded Barbican Dental Care in 1992, said: “I am very excited about the opportunity to grow the business within Bupa Dental Services and look forward to working with Bupa on the initial integration and subsequent expansion of their dental services.”
Oaklins Cavendish, based in the UK, advised the shareholders of Barbican Dental Care in this transaction. The team's specialist commented: “Barbican Dental Care’s unique business-to-business service proposition and high quality, well run private surgeries generated significant interest. Neil has successfully developed the business through his constant focus on the provision of high quality private dental services in state-of-the-art facilities.”
Talk to the deal team
Lord Leigh of Hurley
Oaklins Cavendish
Related deals
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Learn morebioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Learn moreSLT has been acquired by Indutrade
SLT S.r.l. has been acquired by Indutrade AB and will be integrated into the group’s life science business area. The transaction is Indutrade’s fifth acquisition in 2025 and is expected to have a marginally positive impact on the group’s earnings per share.
Learn more